{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:27:57Z","timestamp":1780082877675,"version":"3.54.0"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["F31 MH121023"],"award-info":[{"award-number":["F31 MH121023"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R56 AG AG058661"],"award-info":[{"award-number":["R56 AG AG058661"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R21 AG064774"],"award-info":[{"award-number":["R21 AG064774"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21 NS114870"],"award-info":[{"award-number":["R21 NS114870"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01 HD101402"],"award-info":[{"award-number":["R01 HD101402"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Memantine, a noncompetitive N-methyl-D-aspartate receptor antagonist, has been approved for use in Alzheimer\u2019s disease, but an increasing number of studies have investigated its utility for neuropsychiatric disorders. Here, we characterized a novel compound, fluoroethylnormemtantine (FENM), which was derived from memantine with an extra Fluor in an optimized position for in vivo biomarker labeling. We sought to determine if FENM produced similar behavioral effects as memantine and\/or if FENM has beneficial effects against fear, avoidance, and behavioral despair.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We administered saline, FENM, or memantine prior to a number of behavioral assays, including paired-pulse inhibition, open field, light dark test, forced swim test, and cued fear conditioning in male Wistar rats.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Unlike memantine, FENM did not produce nonspecific side effects and did not alter sensorimotor gating or locomotion. FENM decreased immobility in the forced swim test. Moreover, FENM robustly facilitated fear extinction learning when administered prior to either cued fear conditioning training or tone reexposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results suggest that FENM is a promising, novel compound that robustly reduces fear behavior and may be useful for further preclinical testing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyab007","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T20:11:24Z","timestamp":1614024684000},"page":"519-531","source":"Crossref","is-referenced-by-count":16,"title":["Fluoroethylnormemantine, A Novel Derivative of Memantine, Facilitates Extinction Learning Without Sensorimotor Deficits"],"prefix":"10.1093","volume":"24","author":[{"given":"Briana K","family":"Chen","sequence":"first","affiliation":[{"name":"Doctoral Program in Neurobiology and Behavior, Columbia University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00eblle","family":"Le Pen","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Pathophysiology of Psychiatric Disorders, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Eckmier","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Pathophysiology of Psychiatric Disorders, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Rubinstenn","sequence":"additional","affiliation":[{"name":"ReST Therapeutics, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese M","family":"Jay","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry and Neuroscience of Paris, INSERM U1266, Pathophysiology of Psychiatric Disorders, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A","family":"Denny","sequence":"additional","affiliation":[{"name":"Division of Systems Neuroscience, Research Foundation for Mental Hygiene, Inc.\/New York State Psychiatric Institute, New York, New York, USA"},{"name":"Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"2021071411322520000_CIT0001","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol Psychiatry"},{"key":"2021071411322520000_CIT0002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2005.10.057","article-title":"Involvement of PKA, MAPK\/ERK and CaMKII, but not PKC in the acute antidepressant-like effect of memantine in mice","volume":"395","author":"Almeida","year":"2006","journal-title":"Neurosci Lett"},{"key":"2021071411322520000_CIT0003","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1523\/JNEUROSCI.3114-15.2016","article-title":"Previous ketamine produces an enduring blockade of neurochemical and behavioral effects of uncontrollable stress","volume":"36","author":"Amat","year":"2016","journal-title":"J Neurosci"},{"key":"2021071411322520000_CIT0004","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.biopsych.2016.02.014","article-title":"Ketamine\u2019s antidepressant actions: potential mechanisms in the primate medial prefrontal circuits that represent aversive experience","volume":"79","author":"Arnsten","year":"2016","journal-title":"Biol Psychiatry"},{"key":"2021071411322520000_CIT0005","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/ph6040480","article-title":"NMDA receptor antagonists for treatment of depression","volume":"6","author":"Ates-Alagoz","year":"2013","journal-title":"Pharmaceuticals"},{"key":"2021071411322520000_CIT0006","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2009.10.014","article-title":"Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion","volume":"626","author":"Barkus","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"2021071411322520000_CIT0007","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"2021071411322520000_CIT0008","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2015.10.034","article-title":"BDNF - a key transducer of antidepressant effects","volume":"102","author":"Bj\u00f6rkholm","year":"2016","journal-title":"Neuropharmacology"},{"key":"2021071411322520000_CIT0009","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.biopsych.2015.04.022","article-title":"Ketamine as a prophylactic against stress-induced depressive-like behavior","volume":"79","author":"Brachman","year":"2016","journal-title":"Biol Psychiatry"},{"key":"2021071411322520000_CIT0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41386-019-0540-3","article-title":"Prophylactic efficacy of 5-HT4R agonists against stress","volume":"45","author":"Chen","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"2021071411322520000_CIT0011","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41386-020-0714-z","article-title":"Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine","volume":"45","author":"Chen","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"2021071411322520000_CIT0012","author":"ClinicalTrials.gov","year":"2014"},{"key":"2021071411322520000_CIT0013","author":"ClinicalTrials.gov (NCT02094378)","year":"2014"},{"key":"2021071411322520000_CIT0014","author":"ClinicalTrials.gov (NCT02133001)","year":"2020"},{"key":"2021071411322520000_CIT0015","author":"ClinicalTrials.gov (NCT02192099)","year":"2019"},{"key":"2021071411322520000_CIT0016","author":"ClinicalTrials.gov (NCT02267629)","year":"2017"},{"key":"2021071411322520000_CIT0017","author":"ClinicalTrials.gov (NCT02343289)","year":"2015"},{"key":"2021071411322520000_CIT0018","author":"ClinicalTrials.gov (NCT02345148)","year":"2017"},{"key":"2021071411322520000_CIT0019","author":"ClinicalTrials.gov (NCT02606084)","year":"2019"},{"key":"2021071411322520000_CIT0020","author":"ClinicalTrials.gov (NCT02611505)","year":"2017"},{"key":"2021071411322520000_CIT0021","author":"ClinicalTrials.gov (NCT02674295)","year":"2016"},{"key":"2021071411322520000_CIT0022","author":"ClinicalTrials.gov (NCT02857777)","year":"2017"},{"key":"2021071411322520000_CIT0023","author":"ClinicalTrials.gov (NCT02932943)","year":"2019"},{"key":"2021071411322520000_CIT0024","author":"ClinicalTrials.gov (NCT02943564)","year":"2019"},{"key":"2021071411322520000_CIT0025","author":"ClinicalTrials.gov (NCT02943577)","year":"2019"},{"key":"2021071411322520000_CIT0026","author":"ClinicalTrials.gov (NCT02951988)","year":"2020"},{"key":"2021071411322520000_CIT0027","author":"ClinicalTrials.gov (NCT03002077)","year":"2020"},{"key":"2021071411322520000_CIT0028","author":"ClinicalTrials.gov (NCT03298906)","year":"2017"},{"key":"2021071411322520000_CIT0029","author":"ClinicalTrials.gov (NCT03352453)","year":"2020"},{"key":"2021071411322520000_CIT0030","author":"ClinicalTrials.gov (NCT03560518)","year":"2020"},{"key":"2021071411322520000_CIT0031","author":"ClinicalTrials.gov (NCT03575776)","year":"2020"},{"key":"2021071411322520000_CIT0032","author":"ClinicalTrials.gov (NCT03614156)","year":"2020"},{"key":"2021071411322520000_CIT0033","author":"ClinicalTrials.gov (NCT03668600)","year":"2020"},{"key":"2021071411322520000_CIT0034","author":"ClinicalTrials.gov (NCT03799900)","year":"2019"},{"key":"2021071411322520000_CIT0035","author":"ClinicalTrials.gov (NCT03814733)","year":"2019"},{"key":"2021071411322520000_CIT0036","author":"ClinicalTrials.gov (NCT03855865)","year":"2019"},{"key":"2021071411322520000_CIT0037","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/ijnp\/pyaa075","article-title":"Anti-amnesic and neuroprotective effects of fluoroethylnormemantine in a pharmacological mouse model of Alzheimer\u2019s disease","volume":"24","author":"Couly","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021071411322520000_CIT0038","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"2021071411322520000_CIT0039","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"2021071411322520000_CIT0040","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0025-18.2018","article-title":"Inhibition of a descending prefrontal circuit prevents ketamine-induced stress resilience in females","volume":"5","author":"Dolzani","year":"2018","journal-title":"eNeuro"},{"key":"2021071411322520000_CIT0041","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1038\/npp.2008.53","article-title":"Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer\u2019s disease","volume":"33","author":"Dong","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"2021071411322520000_CIT0042","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021071411322520000_CIT0043","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuroscience.2015.01.008","article-title":"Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-na\u00efve and \u201cdepressed\u201d mice exposed to chronic mild stress","volume":"290","author":"Franceschelli","year":"2015","journal-title":"Neuroscience"},{"key":"2021071411322520000_CIT0044","doi-asserted-by":"crossref","first-page":"19m13191","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I)","volume":"81","author":"Fu","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"2021071411322520000_CIT0045","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.drudis.2016.01.016","article-title":"Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity","volume":"21","author":"Gerhard","year":"2016","journal-title":"Drug Discov Today"},{"key":"2021071411322520000_CIT0046","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41386-019-0380-1","article-title":"Group II metabotropic glutamate receptor blockade promotes stress resilience in mice","volume":"44","author":"Highland","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"2021071411322520000_CIT0047","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021071411322520000_CIT0048","doi-asserted-by":"crossref","first-page":"e17464","DOI":"10.7554\/eLife.17464","article-title":"Hippocampal neurogenesis enhancers promote forgetting of remote fear memory after hippocampal reactivation by retrieval","volume":"5","author":"Ishikawa","year":"2016","journal-title":"Elife"},{"key":"2021071411322520000_CIT0049","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/ijnp\/pyy094","article-title":"Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments","volume":"22","author":"Kadriu","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021071411322520000_CIT0050","doi-asserted-by":"crossref","first-page":"172827","DOI":"10.1016\/j.pbb.2019.172827","article-title":"Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: convergent mechanisms","volume":"188","author":"Kato","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"2021071411322520000_CIT0051","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/mp.2017.220","article-title":"BDNF release and signaling are required for the antidepressant actions of GLYX-13","volume":"23","author":"Kato","year":"2018","journal-title":"Mol Psychiatry"},{"key":"2021071411322520000_CIT0052","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3233\/JAD-161251","article-title":"A meta-analysis of memantine for depression","volume":"57","author":"Kishi","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"2021071411322520000_CIT0053","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3233\/JAD-170424","article-title":"Memantine for Alzheimer\u2019s disease: an updated systematic review and meta-analysis","volume":"60","author":"Kishi","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"2021071411322520000_CIT0054","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00008877-200505000-00004","article-title":"A comparison of the predictive therapeutic and undesired side-effects of the NMDA receptor antagonist, memantine, in mice","volume":"16","author":"Kos","year":"2005","journal-title":"Behav Pharmacol"},{"key":"2021071411322520000_CIT0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fpsyt.2013.00052","article-title":"NMDA receptor activity in neuropsychiatric disorders","volume":"4","author":"Lakhan","year":"2013","journal-title":"Front Psychiatry"},{"key":"2021071411322520000_CIT0056","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnins.2019.00043","article-title":"The role of NMDA receptors in Alzheimer\u2019s disease","volume":"13","author":"Liu","year":"2019","journal-title":"Front Neurosci"},{"key":"2021071411322520000_CIT0057","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.biopsych.2015.02.028","article-title":"Large-scale persistent network reconfiguration induced by ketamine in anesthetized monkeys: relevance to mood disorders","volume":"79","author":"Lv","year":"2016","journal-title":"Biol Psychiatry"},{"key":"2021071411322520000_CIT0058","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.biopsych.2018.02.011","article-title":"Ventral CA3 activation mediates prophylactic ketamine efficacy against stress-induced depressive-like behavior","volume":"84","author":"Mastrodonato","year":"2018","journal-title":"Biol Psychiatry"},{"key":"2021071411322520000_CIT0059","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/npp.2017.19","article-title":"Prophylactic ketamine attenuates learned fear","volume":"42","author":"McGowan","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"2021071411322520000_CIT0060","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1600-0773.1993.tb01351.x","article-title":"Potential antidepressive properties of amantadine, memantine and bifemelane","volume":"72","author":"Moryl","year":"1993","journal-title":"Pharmacol Toxicol"},{"key":"2021071411322520000_CIT0061","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/13543784.2014.852536","article-title":"GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists","volume":"23","author":"Moskal","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"2021071411322520000_CIT0062","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am J Psychiatry"},{"key":"2021071411322520000_CIT0063","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am J Psychiatry"},{"key":"2021071411322520000_CIT0064","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ijnp\/pyaa027","article-title":"Managing esketamine treatment frequency toward successful outcomes: analysis of phase 3 data","volume":"23","author":"Nijs","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021071411322520000_CIT0065","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41380-018-0028-2","article-title":"Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects","volume":"24","author":"Nugent","year":"2019","journal-title":"Mol Psychiatry"},{"key":"2021071411322520000_CIT0066","first-page":"145","article-title":"NMDA Receptors and affective disorders","volume-title":"Antidepressants: New Pharmacological Strategies","author":"Paul","year":"1997"},{"key":"2021071411322520000_CIT0067","article-title":"Population pharmacokinetics of esketamine nasal spray and its metabolite noresketamine in healthy subjects and patients with treatment-resistant depression","author":"Perez-Ruixo","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2021071411322520000_CIT0068","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.biopsych.2017.10.020","article-title":"Common neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant-like effects","volume":"84","author":"Pham","year":"2018","journal-title":"Biol Psychiatry"},{"key":"2021071411322520000_CIT0069","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am J Psychiatry"},{"key":"2021071411322520000_CIT0070","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/266730a0","article-title":"Depression: a new animal model sensitive to antidepressant treatments","volume":"266","author":"Porsolt","year":"1977","journal-title":"Nature"},{"key":"2021071411322520000_CIT0071","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainres.2009.03.037","article-title":"Pharmacotherapy of PTSD: premises, principles, and priorities","volume":"1293","author":"Ravindran","year":"2009","journal-title":"Brain Res"},{"key":"2021071411322520000_CIT0072","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ijnp\/pyaa030","article-title":"Effects of Mu-Opiate receptor gene polymorphism rs1799971 (A118G) on the antidepressant and dissociation responses in esketamine nasal spray clinical trials","volume":"23","author":"Saad","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021071411322520000_CIT0073","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nucmedbio.2015.04.001","article-title":"Radiolabeling of [18F]-fluoroethylnormemantine and initial in vivo evaluation of this innovative PET tracer for imaging the PCP sites of NMDA receptors","volume":"42","author":"Salabert","year":"2015","journal-title":"Nucl Med Biol"},{"key":"2021071411322520000_CIT0074","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.12.003","article-title":"Evaluation of [18F]FNM biodistribution and dosimetry based on whole-body PET imaging of rats","volume":"59","author":"Salabert","year":"2018","journal-title":"Nucl Med Biol"},{"key":"2021071411322520000_CIT0075","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.neuropharm.2011.06.012","article-title":"Pharmacological treatment of PTSD - established and new approaches","volume":"62","author":"Steckler","year":"2012","journal-title":"Neuropharmacology"},{"key":"2021071411322520000_CIT0076","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/npp.2009.7","article-title":"The effects of memantine on prepulse inhibition","volume":"34","author":"Swerdlow","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"2021071411322520000_CIT0077","doi-asserted-by":"crossref","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"2021071411322520000_CIT0078","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12264-014-1504-6","article-title":"Contribution of NMDA receptors to dorsolateral prefrontal cortical networks in primates","volume":"31","author":"Wang","year":"2015","journal-title":"Neurosci Bull"},{"key":"2021071411322520000_CIT0079","doi-asserted-by":"crossref","first-page":"pyw080","DOI":"10.1093\/ijnp\/pyw080","article-title":"Antidepressant effects of (+)-MK-801 and (-)-MK-801 in","volume":"19","author":"Yang","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021071411322520000_CIT0080","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol Psychiatry"},{"key":"2021071411322520000_CIT0081","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40263-018-0492-x","article-title":"Convergent mechanisms underlying rapid antidepressant action","volume":"32","author":"Zanos","year":"2018","journal-title":"CNS Drugs"},{"key":"2021071411322520000_CIT0082","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyab007\/36948942\/pyab007.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/24\/6\/519\/38956575\/pyab007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/24\/6\/519\/38956575\/pyab007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T11:35:35Z","timestamp":1626262535000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/24\/6\/519\/6149959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":82,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,2,25]]},"published-print":{"date-parts":[[2021,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyab007","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,2,25]]}}}